UNASSIGNED: Background: Infiltration of immune cells and immune microenvironment determine the proliferative activity of the @entity5 and @entity3 . The aim of this study was to analyze the influence of activation or suppression of the immune response mediators on the prognosis of @entity1125 ( @entity1125 ). Methods: We searched Pubmed, Web of Science, Embase and The Cochrane Library for relevant literatures until June 2016. The quality of studies was assessed by QUADAS-2 and NOS tools. Forest and funnel plots and all statistical analyses were generated by using Review Manager 5.3. The bias of included studies was estimated by Egger's test using Meta R package. Results: A total of 2339 @entity1 from 12 studies were finally enrolled in this meta-analysis. @entity1 with high expression of immune active factors, intraepithelial @entity5 -infiltrating @entity404 + , @entity405 +, and @entity403 + T lymphocytes, MHC I, @entity3223 , showed a better @entity1349 ( @entity1349 ) than those with low expression (HR=0.52, 95% CI=0.41-0.67, P<0.00001). On the contrary, the high expression of immune suppressive factors ( @entity7406 + neutrophils, Neutrophil-lymphocyte ratio, Intratumoral IL-17+ cells and PD-1+/ @entity405 + TILs) was significantly associated with poor @entity1349 (HR=1.79, 95% CI=1.44-2.22, P<0.00001). A further analysis of therapies targeting @entity5 microenvironment modulation showed that the median progression free survival (PFS) for @entity1125 @entity1 who received adjuvant immunotherapy was longer than those who received surgery or chemotherapy alone, and the estimated pooled mean difference demonstrated a highly significant improvement ( @entity601 =2.33; 95% CI: 0.63-4.02, P=0.007). The total effect of PFS and @entity1349 was statistically longer in experimental group, compared to @entity1 in control groups, respectively (PFS: RR=1.25; 95% CI: 1.08-1.46, P=0.004; @entity1349 : RR=1.16; 95% CI: 1.07-1.27, P=0.0006). In subgroup meta-analysis of studies on 6-, 12- and 18-month PFS and @entity1349 , it showed that adjuvant immunotherapy could improve the 6-month PFS (RR=1.23; 95% CI: 1.05-1.44, P=0.009), and 6-month @entity1349 (RR=1.17; 95% CI: 1.06-1.30, P=0.002). Conclusions: So given the above issue, our meta-analysis confirmed that the level of immune mediators could be a predicative factor for prognosis of @entity1125 @entity1 , and immunotherapy regimens by modulating the @entity5 microenvironment was superior for enhancing median PFS, 6-month PFS and @entity1349 .

Activation or suppression of the immune response mediators in @entity1125 ( @entity1125 ) XXXX : a systematic review and meta-analysis.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity3223 :: ('22914', 'Gene') :: ['NKG2D'] @entity404 :: ('920', 'Gene') :: ['CD4'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity7406 :: ('1088', 'Gene') :: ['CD66b'] @entity601 :: ('MESH:D009436', 'Disease') :: ['MD'] @entity403 :: ('50943', 'Gene') :: ['Foxp3'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity405 :: ('925', 'Gene') :: ['CD8'] @entity1125 :: ('MESH:D001661', 'Disease') :: ['biliary tract cancer', 'BTC'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity1 :: (9606,Species) :: ['patients']
